NASDAQ:HCWB HCW Biologics (HCWB) Stock Price, News & Analysis $4.13 -0.11 (-2.59%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$4.20 +0.08 (+1.82%) As of 08/1/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About HCW Biologics Stock (NASDAQ:HCWB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HCW Biologics alerts:Sign Up Key Stats Today's Range$4.05▼$4.1950-Day Range$3.75▼$8.3752-Week Range$3.55▼$100.80Volume19,934 shsAverage Volume113,650 shsMarket Capitalization$5.94 millionP/E RatioN/ADividend YieldN/APrice Target$35.00Consensus RatingBuy Company Overview HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida. Read More HCW Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreHCWB MarketRank™: HCW Biologics scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingHCW Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageHCW Biologics has only been the subject of 1 research reports in the past 90 days.Read more about HCW Biologics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of HCW Biologics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HCW Biologics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about HCW Biologics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.84% of the float of HCW Biologics has been sold short.Short Interest Ratio / Days to CoverHCW Biologics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HCW Biologics has recently decreased by 65.99%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHCW Biologics does not currently pay a dividend.Dividend GrowthHCW Biologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.84% of the float of HCW Biologics has been sold short.Short Interest Ratio / Days to CoverHCW Biologics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HCW Biologics has recently decreased by 65.99%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for HCWB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, HCW Biologics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $305,032.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders42.70% of the stock of HCW Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.96% of the stock of HCW Biologics is held by institutions.Read more about HCW Biologics' insider trading history. Receive HCWB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HCW Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address HCWB Stock News HeadlinesHCW Biologics Inc News (HCWB) - Investing.comJuly 2, 2025 | investing.comInsiders Re-Evaluate Their US$3.05m Stock Purchase As HCW Biologics Falls To US$6.9mJuly 2, 2025 | uk.finance.yahoo.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.August 2 at 2:00 AM | Brownstone Research (Ad)HCW Biologics Completes Warrant Exercise with ArmisticeJuly 1, 2025 | tipranks.comHCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid TumorsJune 27, 2025 | globenewswire.comHCW Biologics Inc.: HCW Biologics Regains Compliance with Nasdaq Capital Market RequirementsJune 26, 2025 | finanznachrichten.deHCW Biologics Regains Nasdaq Compliance as of June 2025June 26, 2025 | tipranks.comHCW Biologics Regains Compliance with Nasdaq Capital Market RequirementsJune 26, 2025 | globenewswire.comSee More Headlines HCWB Stock Analysis - Frequently Asked Questions How have HCWB shares performed this year? HCW Biologics' stock was trading at $17.8440 on January 1st, 2025. Since then, HCWB stock has decreased by 76.9% and is now trading at $4.13. How were HCW Biologics' earnings last quarter? HCW Biologics Inc. (NASDAQ:HCWB) posted its earnings results on Thursday, May, 15th. The company reported ($0.05) EPS for the quarter. When did HCW Biologics' stock split? HCW Biologics's stock reverse split on the morning of Friday, April 11th 2025.The 1-40 reverse split was announced on Tuesday, April 1st 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did HCW Biologics IPO? HCW Biologics (HCWB) raised $45 million in an initial public offering (IPO) on Tuesday, July 20th 2021. The company issued 5,600,000 shares at $8.00 per share. EF Hutton served as the underwriter for the IPO and Revere Securities was co-manager. How do I buy shares of HCW Biologics? Shares of HCWB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of HCW Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that HCW Biologics investors own include Jiuzi (JZXN), Faraday Future Intelligent Electric (FFIE), AMC Entertainment (AMC), Kiora Pharmaceuticals (KPRX), Rallybio (RLYB), Adial Pharmaceuticals (ADIL) and Aridis Pharmaceuticals (ARDS). Company Calendar Last Earnings5/15/2025Today8/02/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HCWB CIK1828673 Webwww.hcwbiologics.com Phone954-842-2024Fax954-842-2037Employees40Year FoundedN/APrice Target and Rating Average Price Target for HCW Biologics$35.00 High Price Target$35.00 Low Price Target$35.00 Potential Upside/Downside+747.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($23.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$30.02 million Net Margins-1,712.94% Pretax Margin-1,713.01% Return on EquityN/A Return on Assets-90.09% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$1.45 million Price / Sales4.11 Cash FlowN/A Price / Cash FlowN/A Book Value($6.08) per share Price / Book-0.68Miscellaneous Outstanding Shares1,439,000Free Float825,000Market Cap$5.94 million OptionableNot Optionable Beta0.65 Social Links 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:HCWB) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HCW Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HCW Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.